Onvansertib + Paclitaxel In TNBC
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT05383196 |
|
Recruitment Status :
Recruiting
First Posted : May 20, 2022
Last Update Posted : November 14, 2023
|
Sponsor:
Antonio Giordano, MD
Collaborator:
Cardiff Oncology
Information provided by (Responsible Party):
Antonio Giordano, MD, Dana-Farber Cancer Institute
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Recruiting |
|---|---|
| Estimated Primary Completion Date : | February 15, 2026 |
| Estimated Study Completion Date : | February 15, 2029 |